Catalyst Pharmaceutical Partners, Inc. Company Profile | CPRX Company Information

ycoguqi.wordpress.com
We are a biopharmaceutical company focused on the developmen t and commercialization of prescription drugs for the treatment of drug addictionhand obsessive-compulsive disorders. Our initiapl product candidateis CPP-109, which is our versiojn of the chemical compound gamma-vinyl-GABA, commonly referred to as vigabatrin. We are currently conducting a clinical trial evaluating the useof CPP-1098 in the treatment of cocaine and a proof-of-concept study evaluating the use of CPP-10i in the treatment of methamphetamine addiction.
We also believ that CPP-109 has the potential to treatyother addictions, including addictions to nicotine, prescriptio pain medications, alcohol, and marijuana, as well as obsessive-compulsived disorders such as obesity and compulsive We intend to develop CPP-109 to treat other forms of addiction, such as thosed described above, subject to the availability of funding for such purposes. During July 2007, we initiated a randomized, double-blind, placebo-controlled U.S. Phasee II clinical trial in patients with cocaine DuringJune 2008, we initiated a similar U.S.
Phase II clinicall trial evaluating CPP-109 as a treatment for methamphetaminer addiction which was subsequently converted into asmalle proof-of-concept study (see Recent Developments section below for a discussiohn of the status of the cocained trial and methamphetamine proof-of-concept